Cross-referencing clinical data
A pairing appears on this page only when a trial gave both ingredients together and measured the result. Kratom has none that clears that bar.
Stitching two separate single-ingredient studies into a pairing is the one thing this engine will not do. When a study of the combination itself holds up at source, it lands here with its citation.
No invented synergy. Where actives were studied on their own rather than together, the record shows each on its own evidence, never a combined effect no trial measured.
Research strength. Research strength says how much work stands behind the combination. It is never a product score.
Independent record. Every finding is cited to a named trial, dated, and never written by the brand.
20 pairings are live across the library today. Checked 20 July 2026.
No study gave these as a pair, so they are not in the card above. But the reason they belong together is settled biochemistry, not a guess, so it is worth knowing.
Mitragynine has documented activity at opioid and adrenergic receptors, and caffeine is an adenosine antagonist with its own pressor effect. Taken together the effects on heart rate and blood pressure can stack in a way neither predicts alone. A case report describes right ventricular dysfunction associated with kratom, which is a signal to take seriously rather than a demonstrated dose response.
Passionflower is mild on its own, which is exactly why it gets stacked without much thought. Layered onto mitragynine the sedative burden rises. No controlled work has quantified the combination.
Combining a serotonin precursor with an agent that has any serotonergic activity raises theoretical concern about excessive serotonergic tone. The receptor pharmacology of mitragynine is still being characterised and the size of the serotonergic contribution is unclear. Flagging the direction is the honest position.
Induction of CYP3A4 accelerates mitragynine clearance and lowers exposure, and stopping the inducer removes that effect over days to weeks. The result is an unpredictable exposure profile in either direction. This is the kind of interaction people do not anticipate because both products are sold as botanicals.
Inhibition of clearance raises exposure to a compound whose dose response is already steep and poorly mapped. The in vitro inhibition data does not reliably predict what happens at dietary curcumin intakes. Read it as mechanistic rather than clinical.
Mitragynine is a CYP3A4 substrate, so intestinal inhibition increases the fraction reaching circulation. The inhibition lasts until enzyme is resynthesised, which takes days, so timing the two apart does not solve it. This is one of the better characterised food interactions in pharmacology.
Opioid receptor agonism reduces propulsive motility and increases fluid absorption in the colon, which is why the effect is so reliable. Osmotic magnesium works by an unrelated mechanism and does not counter the receptor activity itself. This is symptom management, not correction of the cause.
Products marketing a piperine boosted botanical rarely spell out that the boost is inhibition of clearance. With an alkaloid of narrow and uncertain exposure margins, raising exposure without changing the label dose is a real hazard. Regard the pairing as raising exposure, not improving quality.
Nothing specific on file for Kratom. Match the label to the daily amount above, and tell your doctor what you take.
Not medical advice. Show the label to your pharmacist.These are the studies our verdict leans on, chosen from the 7 we read for Kratom. The full linked list is below.
12 sources behind our Kratom verdict: peer-reviewed studies and registered clinical trials. Every one links straight to PubMed, the journal, or ClinicalTrials.gov. Read them yourself.
Evidence surfaced via Semantic Scholar (Allen Institute for AI) and ClinicalTrials.gov. Ranked by study type and citation weight, not cherry-picked.
Read this carefully. These are 1,219 voluntary, unverified reactions reported to the FDA (openFDA). The number mostly reflects how popular Kratom is, not how risky it is. A report is not proof Kratom caused anything. It is a signal of what to watch for, nothing more.
Source: openFDA adverse-event reports. Voluntary reporting, not an incidence rate.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.